Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

BACKGROUND

Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT).

METHODS

This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/-carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR.

RESULTS

In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25-2.04) and at EOT 1.53 (IQR: 0.96-2.22). Baseline dNLR showed positive correlation with increased tumor size (

CONCLUSIONS

High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.

Informations de copyright

Copyright © 2022 Ocaña, Chacón, Calvo, Antón, Mansutti, Albanell, Martínez, Lahuerta, Bisagni, Bermejo, Semiglazov, Thill, Chan, Morales, Herranz, Tusquets, Chiesa, Caballero, Valagussa, Bianchini, Alba and Gianni.

Déclaration de conflit d'intérêts

AO is currently an employee of Symphogen, Denmark. MM has received honoraria from Pierre Fabre and support for attending meetings and/or travel from Eisai, Novartis, Pfizer, Pierre Fabre, and Roche. He has received advisory board honoraria from Amgen, Astra Zeneca, Eli Lilly, Gentili, MSD Italia, Novartis, Pfizer, and Roche. JA has received advisory board honoraria from Roche, Lilly, Merck, Daiichi-Sankyo/Astrazeneca, and Seagen and a speaker’s honoraria from Pfizer. GBia has received honoraria from Pfizer, Roche, AstraZeneca, Lilly, Novartis, Noepharm Israel, Amgen, MSD, Chugai, Sanofi, Daiichi Sankyo, Eisai, Gilead, Seagen, and Exact Science. EA has received advisory board honoraria from Roche, Novartis, Pfizer, Lilly, BMS, Genomic Health, and Nanostring and support for attending meetings and/or travel from Celgene, as well as investigation grants from Roche, Pfizer, Sysmex, MSD, and Nanostring. LG has received advisory board honoraria from ADC Therapeutics, AstraZeneca, Celgene, Eli Lilly, G1 Therapeutics, Genentech, Genomic Health, Merck Sharp & Dohme, Oncolytics Biotech, Odonate Therapeutics, Onkaido Therapeutics, Roche, Pfizer, Taiho Pharmaceutical, Hexal Sandoz, Seattle Genetics, Synthon, Zymeworks, and Sanofi-Aventis; consultant honoraria for selected programs of Forty Seven (CD47), GENENTA, METIS Precision Medicine, Novartis, Odonate Therapeutics, Revolution Medicines, Synaffix, Zymeworks, Menarini Ricerche, Amgen, and Biomedical Insights; and research support from Zymeworks, Revolution Medicines (his institution). LG is coinventor of “European Patent Application N.12195182.6 and 12196177.5,” titled “PDL-1 expression in anti-HER2 therapy”—Roche (no compensation provided). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.